WO2004009618A2
(en)
|
2002-07-18 |
2004-01-29 |
Crucell Holland B.V. |
Recombinant production of mixtures of antibodies
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
US20050144655A1
(en)
|
2000-10-31 |
2005-06-30 |
Economides Aris N. |
Methods of modifying eukaryotic cells
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
EP1639009B1
(en)
|
2003-05-30 |
2013-02-27 |
Merus B.V. |
Fab library for the preparation of a mixture of antibodies
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
US8945558B2
(en)
|
2005-10-21 |
2015-02-03 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for treating myocardial infarction comprising administering an IL-6 inhibitor
|
WO2007114319A1
(ja)
|
2006-03-31 |
2007-10-11 |
Chugai Seiyaku Kabushiki Kaisha |
抗体の血中動態を制御する方法
|
JP5754875B2
(ja)
|
2006-04-07 |
2015-07-29 |
国立大学法人大阪大学 |
筋再生促進剤
|
US8080248B2
(en)
*
|
2006-06-02 |
2011-12-20 |
Regeneron Pharmaceuticals, Inc. |
Method of treating rheumatoid arthritis with an IL-6R antibody
|
ATE537190T1
(de)
|
2006-06-02 |
2011-12-15 |
Regeneron Pharma |
Hochaffine antikörper gegen den humanen il-6- rezeptor
|
WO2008020079A1
(en)
|
2006-08-18 |
2008-02-21 |
Ablynx N.V. |
Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
|
US7608693B2
(en)
|
2006-10-02 |
2009-10-27 |
Regeneron Pharmaceuticals, Inc. |
High affinity human antibodies to human IL-4 receptor
|
CA2670583A1
(en)
*
|
2006-11-30 |
2008-06-05 |
Medimmune, Llc |
Antibodies specific for the complex of interleukin-6 and the interleukin-6 receptor
|
NO347649B1
(no)
|
2006-12-14 |
2024-02-12 |
Regeneron Pharma |
Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
|
AU2008208321B2
(en)
|
2007-01-23 |
2013-03-21 |
Chugai Seiyaku Kabushiki Kaisha |
Chronic rejection inhibitor
|
US8252286B2
(en)
|
2007-05-21 |
2012-08-28 |
Alderbio Holdings Llc |
Antagonists of IL-6 to prevent or treat thrombosis
|
US9701747B2
(en)
|
2007-05-21 |
2017-07-11 |
Alderbio Holdings Llc |
Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
|
US8178101B2
(en)
*
|
2007-05-21 |
2012-05-15 |
Alderbio Holdings Inc. |
Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
|
US7906117B2
(en)
|
2007-05-21 |
2011-03-15 |
Alderbio Holdings Llc |
Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
|
US8062864B2
(en)
*
|
2007-05-21 |
2011-11-22 |
Alderbio Holdings Llc |
Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
|
NZ581418A
(en)
*
|
2007-05-21 |
2012-08-31 |
Alderbio Holdings Llc |
Novel rabbit antibody humanization methods and humanized rabbit antibodies
|
KR101829776B1
(ko)
|
2007-05-21 |
2018-02-19 |
앨더바이오 홀딩스 엘엘씨 |
Il-6에 대한 항체 및 이의 용도
|
US8404235B2
(en)
|
2007-05-21 |
2013-03-26 |
Alderbio Holdings Llc |
Antagonists of IL-6 to raise albumin and/or lower CRP
|
US20090238825A1
(en)
*
|
2007-05-21 |
2009-09-24 |
Kovacevich Brian R |
Novel rabbit antibody humanization methods and humanized rabbit antibodies
|
EP2572729A3
(en)
|
2007-08-10 |
2013-06-05 |
Regeneron Pharmaceuticals, Inc. |
High affinity human antibodies to human nerve growth factor
|
TWI464262B
(zh)
|
2007-09-26 |
2014-12-11 |
中外製藥股份有限公司 |
抗體固定區的變異
|
JP5334319B2
(ja)
*
|
2007-09-26 |
2013-11-06 |
中外製薬株式会社 |
Cdrのアミノ酸置換により抗体の等電点を改変する方法
|
AU2008304756B8
(en)
|
2007-09-26 |
2015-02-12 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-IL-6 receptor antibody
|
PL2708558T3
(pl)
|
2008-04-11 |
2018-09-28 |
Chugai Seiyaku Kabushiki Kaisha |
Cząsteczka wiążąca antygen zdolna do wiązania dwóch lub więcej cząsteczek antygenu w sposób powtarzalny
|
WO2009140348A2
(en)
|
2008-05-13 |
2009-11-19 |
Novimmune Sa |
Anti-il-6/il-6r antibodies and methods of use thereof
|
EP2288623B1
(en)
*
|
2008-05-23 |
2013-07-10 |
Ablexis, LLC |
Method of generating single vl domain antibodies in transgenic animals
|
CN104906581A
(zh)
*
|
2008-06-05 |
2015-09-16 |
国立研究开发法人国立癌症研究中心 |
神经浸润抑制剂
|
PL2147594T3
(pl)
|
2008-06-27 |
2014-04-30 |
Merus Nv |
Wytwarzające przeciwciała ssaki inne niż człowiek
|
TWI440469B
(zh)
*
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
AU2012200724B8
(en)
*
|
2008-09-26 |
2014-09-11 |
Chugai Seiyaku Kabushiki Kaisha |
Improved antibody molecules
|
CA2742786A1
(en)
|
2008-11-13 |
2010-05-20 |
Femta Pharmaceuticals, Inc. |
Humanized anti-il-6 antibodies
|
US9212223B2
(en)
|
2008-11-25 |
2015-12-15 |
Alderbio Holdings Llc |
Antagonists of IL-6 to prevent or treat thrombosis
|
US8323649B2
(en)
|
2008-11-25 |
2012-12-04 |
Alderbio Holdings Llc |
Antibodies to IL-6 and use thereof
|
US9452227B2
(en)
|
2008-11-25 |
2016-09-27 |
Alderbio Holdings Llc |
Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
|
US8420089B2
(en)
|
2008-11-25 |
2013-04-16 |
Alderbio Holdings Llc |
Antagonists of IL-6 to raise albumin and/or lower CRP
|
US8992920B2
(en)
|
2008-11-25 |
2015-03-31 |
Alderbio Holdings Llc |
Anti-IL-6 antibodies for the treatment of arthritis
|
US8337847B2
(en)
|
2008-11-25 |
2012-12-25 |
Alderbio Holdings Llc |
Methods of treating anemia using anti-IL-6 antibodies
|
JO3672B1
(ar)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
CA2744103C
(en)
*
|
2009-02-24 |
2018-01-02 |
Esbatech, An Alcon Biomedical Research Unit Llc |
Methods for identifying immunobinders of cell-surface antigens
|
BRPI1005398A2
(pt)
*
|
2009-02-24 |
2019-03-26 |
Esbatech, An Alcon Biomedical Research Unit Llc |
métodos para identificação de imunoligantes de antígenos na superfície celular.
|
JP5717624B2
(ja)
|
2009-03-19 |
2015-05-13 |
中外製薬株式会社 |
抗体定常領域改変体
|
AR075908A1
(es)
*
|
2009-03-19 |
2011-05-04 |
Chugai Pharmaceutical Co Ltd |
Formulacion farmaceutica que contiene moleculas de anticuerpo mejoradas, polipeptidos. metodo para estabilizar solucion, anticuerpo.
|
TWI682995B
(zh)
|
2009-03-19 |
2020-01-21 |
日商中外製藥股份有限公司 |
抗體恆定區域改變體
|
GB0905023D0
(en)
|
2009-03-24 |
2009-05-06 |
Univ Erasmus Medical Ct |
Binding molecules
|
EP2417162A2
(en)
*
|
2009-04-10 |
2012-02-15 |
Ablynx N.V. |
Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
|
EP2417163B1
(en)
|
2009-04-10 |
2019-02-27 |
Ablynx N.V. |
Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
|
US20120204278A1
(en)
|
2009-07-08 |
2012-08-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
US9445581B2
(en)
|
2012-03-28 |
2016-09-20 |
Kymab Limited |
Animal models and therapeutic molecules
|
DK3028565T3
(da)
|
2009-07-08 |
2017-11-13 |
Kymab Ltd |
Dyremodeller og terapeutiske molekyler
|
WO2011066371A2
(en)
|
2009-11-24 |
2011-06-03 |
Alder Biopharmaceuticals, Inc. |
Antibodies to il-6 and use thereof
|
JO3182B1
(ar)
|
2009-07-29 |
2018-03-08 |
Regeneron Pharma |
مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
|
KR101860175B1
(ko)
|
2009-10-26 |
2018-05-21 |
에프. 호프만-라 로슈 아게 |
글리코실화된 면역글로불린의 제조 방법
|
US9775921B2
(en)
|
2009-11-24 |
2017-10-03 |
Alderbio Holdings Llc |
Subcutaneously administrable composition containing anti-IL-6 antibody
|
KR101553244B1
(ko)
|
2009-12-10 |
2015-09-15 |
리제너론 파마슈티칼스 인코포레이티드 |
중쇄 항체를 만드는 마우스
|
JO3274B1
(ar)
|
2009-12-24 |
2018-09-16 |
Regeneron Pharma |
أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
|
JO3417B1
(ar)
|
2010-01-08 |
2019-10-20 |
Regeneron Pharma |
الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
|
AR080428A1
(es)
|
2010-01-20 |
2012-04-11 |
Chugai Pharmaceutical Co Ltd |
Formulaciones liquidas estabilizadas contentivas de anticuerpos
|
JO3183B1
(ar)
|
2010-01-29 |
2018-03-08 |
Regeneron Pharma |
طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
|
US20120021409A1
(en)
|
2010-02-08 |
2012-01-26 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
ES2603559T5
(es)
|
2010-02-08 |
2021-02-22 |
Regeneron Pharma |
Cadena ligera común de ratón
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
EP3190187A1
(en)
*
|
2010-05-21 |
2017-07-12 |
Peptimed, Inc. |
Reagents and methods for treating cancer
|
JO3340B1
(ar)
|
2010-05-26 |
2019-03-13 |
Regeneron Pharma |
مضادات حيوية لـعامل تمايز النمو 8 البشري
|
JP6051049B2
(ja)
|
2010-05-28 |
2016-12-21 |
中外製薬株式会社 |
抗腫瘍t細胞応答増強剤
|
CN103221063B
(zh)
|
2010-06-16 |
2016-08-24 |
特瑞利斯生物科学有限责任公司 |
针对人类巨细胞病毒(cmv)gb蛋白质的高亲和力人类抗体
|
MX2018014787A
(es)
|
2010-08-02 |
2023-02-14 |
Regeneron Pharma |
Ratones que producen proteinas de union que comprenden dominios vl.
|
US9533039B2
(en)
|
2010-09-27 |
2017-01-03 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies
|
AR083044A1
(es)
*
|
2010-09-27 |
2013-01-30 |
Regeneron Pharma |
Anticuerpos anti-cd48 y usos de los mismos
|
JO3375B1
(ar)
|
2010-11-08 |
2019-03-13 |
Regeneron Pharma |
أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
|
JO3756B1
(ar)
*
|
2010-11-23 |
2021-01-31 |
Regeneron Pharma |
اجسام مضادة بشرية لمستقبلات الجلوكاجون
|
EP2643016A2
(en)
|
2010-11-23 |
2013-10-02 |
Alder Biopharmaceuticals, Inc. |
Anti-il-6 antibodies for the treatment of anemia
|
WO2012073992A1
(ja)
|
2010-11-30 |
2012-06-07 |
中外製薬株式会社 |
複数分子の抗原に繰り返し結合する抗原結合分子
|
WO2012098238A1
(en)
|
2011-01-21 |
2012-07-26 |
Novimmune S.A. |
Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists
|
PL2738258T5
(pl)
|
2011-02-25 |
2023-05-15 |
Regeneron Pharmaceuticals, Inc. |
Myszy adam6
|
RU2013144392A
(ru)
|
2011-03-03 |
2015-04-10 |
Апексиджен, Инк. |
Антитела к рецептору il-6 и способы применения
|
JP6182066B2
(ja)
|
2011-04-01 |
2017-08-16 |
中外製薬株式会社 |
組換えポリペプチドの製造方法
|
PT2631654E
(pt)
|
2011-05-12 |
2015-08-21 |
Regeneron Pharma |
Ensaio de libertação de neuropéptidos para canais de sódio
|
JO3412B1
(ar)
|
2011-06-17 |
2019-10-20 |
Regeneron Pharma |
أجسام مضادة ل angptl3 واستخداماتها
|
AR087305A1
(es)
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
ES2872081T3
(es)
|
2011-08-05 |
2021-11-02 |
Regeneron Pharma |
Ratones con cadena ligera universal humanizada
|
EP4091442A1
(en)
|
2011-09-19 |
2022-11-23 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
US10138302B2
(en)
|
2011-09-23 |
2018-11-27 |
Ablynx N.V. |
Methods for treating rheumatoid arthritis by administering interleukin-6 receptor antibodies
|
CA2791109C
(en)
|
2011-09-26 |
2021-02-16 |
Merus B.V. |
Generation of binding molecules
|
EP2761008A1
(en)
|
2011-09-26 |
2014-08-06 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
IN2014CN03042A
(pt)
|
2011-09-30 |
2015-07-03 |
Regeneron Pharma |
|
SG10201914052TA
(en)
*
|
2011-10-11 |
2020-03-30 |
Sanofi Biotechnology |
Compositions for the treatment of rheumatoid arthritis and methods of using same
|
US9943594B2
(en)
|
2011-10-11 |
2018-04-17 |
Sanofi Biotechnology |
Methods for the treatment of rheumatoid arthritis
|
TWI589299B
(zh)
*
|
2011-10-11 |
2017-07-01 |
再生元醫藥公司 |
用於治療類風濕性關節炎之組成物及其使用方法
|
WO2013059230A1
(en)
|
2011-10-17 |
2013-04-25 |
Regeneron Pharmaceuticals, Inc. |
Restricted immunoglobulin heavy chain mice
|
WO2013059548A1
(en)
|
2011-10-19 |
2013-04-25 |
Sanofi |
Compositions and methods for treating cancer using jak2 inhibitor
|
WO2013059426A1
(en)
*
|
2011-10-21 |
2013-04-25 |
The Regents Of The University Of California |
Human endogenous retrovirus peptides, antibodies to the peptides, and methods of use thereof
|
CN103059137A
(zh)
*
|
2011-10-21 |
2013-04-24 |
神州细胞工程有限公司 |
抗hIL6R高亲和力抗体的制备及应用
|
US8878001B2
(en)
|
2011-10-28 |
2014-11-04 |
Regeneron Pharmaceuticals, Inc. |
Humanized IL-6 and IL-6 receptor
|
JO3370B1
(ar)
|
2011-11-10 |
2019-03-13 |
Regeneron Pharma |
طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
|
PT2780368T
(pt)
|
2011-11-14 |
2018-03-22 |
Regeneron Pharma |
Composições e métodos para aumentar a massa muscular e a força muscular antagonizando especificamente gdf8 e/ou activina a
|
PL2782598T3
(pl)
|
2011-11-23 |
2021-03-08 |
In3Bio Ltd. |
Rekombinowane białka i ich zastosowania terapeutyczne
|
US9253965B2
(en)
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
JP6327750B2
(ja)
|
2011-12-20 |
2018-05-23 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
ヒト化軽鎖マウス
|
LT2809681T
(lt)
|
2012-01-31 |
2019-02-11 |
Regeneron Pharmaceuticals, Inc. |
Antikūnai prieš asic1 ir jų panaudojimas
|
US9371383B2
(en)
|
2012-01-31 |
2016-06-21 |
Regeneron Pharmaceuticals, Inc. |
Anti-ASIC1 antibodies and uses thereof
|
TWI613215B
(zh)
|
2012-02-22 |
2018-02-01 |
再生元醫藥公司 |
抗-大-內皮素-1(big-et-1)抗體及其用途
|
CN108101983A
(zh)
|
2012-03-02 |
2018-06-01 |
瑞泽恩制药公司 |
艰难梭状芽孢杆菌毒素的人源抗体
|
JP2015509380A
(ja)
|
2012-03-06 |
2015-03-30 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
共通の軽鎖のマウス
|
PL2825037T4
(pl)
|
2012-03-16 |
2020-03-31 |
Regeneron Pharmaceuticals, Inc. |
Gryzonie eksprymujące sekwencje immunoglobuliny wrażliwej na pH
|
CA2865644A1
(en)
|
2012-03-16 |
2013-09-19 |
Regeneron Pharmaceuticals, Inc. |
Mice that produce antigen-binding proteins with ph-dependent binding characteristics
|
US20140013456A1
(en)
|
2012-03-16 |
2014-01-09 |
Regeneron Pharmaceuticals, Inc. |
Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
|
KR102228296B1
(ko)
|
2012-03-16 |
2021-03-17 |
리제너론 파마슈티칼스 인코포레이티드 |
히스티딘 공학처리된 경쇄 항체 및 그것을 생성하기 위한 유전자 변형된 비-사람 동물
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
TWI619729B
(zh)
|
2012-04-02 |
2018-04-01 |
再生元醫藥公司 |
抗-hla-b*27抗體及其用途
|
LT2838918T
(lt)
|
2012-04-20 |
2019-09-10 |
Merus N.V. |
Būdai ir priemonės heterodimerinių ig-tipo molekulių gamybai
|
JO3820B1
(ar)
|
2012-05-03 |
2021-01-31 |
Regeneron Pharma |
أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
|
KR20240042174A
(ko)
|
2012-06-12 |
2024-04-01 |
리제너론 파마슈티칼스 인코포레이티드 |
제한된 면역글로불린 중쇄 유전자좌를 가지는 인간화된 비-인간 동물
|
TW201843172A
(zh)
|
2012-06-25 |
2018-12-16 |
美商再生元醫藥公司 |
抗-egfr抗體及其用途
|
PT4011915T
(pt)
|
2012-08-21 |
2024-01-02 |
Regeneron Pharma |
Métodos para o tratamento ou prevenção da asma através da administração de um antagonista de il-4r
|
JO3462B1
(ar)
|
2012-08-22 |
2020-07-05 |
Regeneron Pharma |
أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
|
NZ731864A
(en)
|
2012-09-07 |
2022-07-01 |
Regeneron Pharma |
Methods for treating atopic dermatitis by administering an il-4r antagonist
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
JP2016502520A
(ja)
|
2012-11-13 |
2016-01-28 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
抗プロキネチシン受容体(prokr)抗体およびその使用
|
JO3405B1
(ar)
|
2013-01-09 |
2019-10-20 |
Regeneron Pharma |
الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
|
SG11201505383UA
(en)
|
2013-02-20 |
2015-08-28 |
Regeneron Pharma |
Non-human animals with modified immunoglobulin heavy chain sequences
|
KR102295842B1
(ko)
|
2013-03-13 |
2021-08-31 |
리제너론 파마슈티칼스 인코포레이티드 |
제한된 면역글로불린 경쇄 레퍼토리를 발현하는 마우스
|
JO3532B1
(ar)
|
2013-03-13 |
2020-07-05 |
Regeneron Pharma |
الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
|
WO2014160179A1
(en)
|
2013-03-13 |
2014-10-02 |
Regeneron Pharmaceuticals, Inc. |
Common light chain mouse
|
SG10201707518YA
(en)
|
2013-03-14 |
2017-10-30 |
Regeneron Pharma |
Human antibodies to grem 1
|
CA2902572A1
(en)
|
2013-03-14 |
2014-10-02 |
Regeneron Pharmaceuticals, Inc. |
Human antibodies to nav1.7
|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
US9788534B2
(en)
|
2013-03-18 |
2017-10-17 |
Kymab Limited |
Animal models and therapeutic molecules
|
US9783618B2
(en)
|
2013-05-01 |
2017-10-10 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
US11707056B2
(en)
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
WO2014200018A1
(ja)
|
2013-06-11 |
2014-12-18 |
独立行政法人 国立精神・神経医療研究センター |
再発寛解型多発性硬化症(rrms)患者の治療予後予測方法、及び新規治療適応判断方法
|
RS59354B1
(sr)
|
2013-06-21 |
2019-10-31 |
Sanofi Biotechnology |
Postupci lečenja nosne polipoze davanjem il-4r antagonista
|
TWI655207B
(zh)
|
2013-07-30 |
2019-04-01 |
再生元醫藥公司 |
抗活化素a之抗體及其用途
|
EP3564671B1
(en)
|
2013-08-23 |
2021-09-29 |
Regeneron Pharmaceuticals, Inc. |
Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
|
RU2019121863A
(ru)
|
2013-09-18 |
2019-08-29 |
Регенерон Фармасьютикалз, Инк. |
Антитела со встроенным в легкие цепи гистидином и генетически модифицированные отличные от человека животные для их получения
|
GB201316644D0
(en)
|
2013-09-19 |
2013-11-06 |
Kymab Ltd |
Expression vector production & High-Throughput cell screening
|
SG11201602236SA
(en)
|
2013-10-01 |
2016-04-28 |
Kymab Ltd |
Animal models and therapeutic molecules
|
BR112016009460B1
(pt)
|
2013-10-31 |
2020-09-29 |
Regeneron Pharmaceuticals, Inc. |
Método para detectar a presença de anticorpos neutralizantes
|
JP6483117B2
(ja)
|
2013-11-20 |
2019-03-13 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
Aplnrモジュレーター及びその使用
|
US8945560B1
(en)
|
2014-07-15 |
2015-02-03 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
DE202014010499U1
(de)
|
2013-12-17 |
2015-10-20 |
Kymab Limited |
Targeting von humaner PCSK9 zur Cholesterinbehandlung
|
US9017678B1
(en)
|
2014-07-15 |
2015-04-28 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
WO2015095511A2
(en)
*
|
2013-12-20 |
2015-06-25 |
The Scripps Research Institute |
Functional antibodies that modulate cell death and related methods
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對pd-1的人類抗體
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗pd-l1之人類抗體
|
WO2015116852A1
(en)
*
|
2014-01-29 |
2015-08-06 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating rheumatoid arthritis by administering an il-6r antibody
|
RS59077B1
(sr)
|
2014-03-11 |
2019-09-30 |
Regeneron Pharma |
Anti-egfrviii antitela i njihova primena
|
TWI701042B
(zh)
|
2014-03-19 |
2020-08-11 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
JP6636498B2
(ja)
|
2014-03-21 |
2020-01-29 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
単一ドメイン結合タンパク質を作る非ヒト動物
|
EP3119811B1
(en)
|
2014-03-21 |
2019-10-30 |
Regeneron Pharmaceuticals, Inc. |
Vl antigen binding proteins exhibiting distinct binding characteristics
|
JO3701B1
(ar)
|
2014-05-23 |
2021-01-31 |
Regeneron Pharma |
مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
|
PT3107575T
(pt)
|
2014-09-15 |
2021-11-18 |
Regeneron Pharma |
Métodos de tratamento e prevenção de asma administrando um antagonista de il-4r
|
JP2017533695A
(ja)
|
2014-09-16 |
2017-11-16 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
抗グルカゴン抗体およびその使用
|
SG10201913084PA
(en)
|
2014-09-23 |
2020-03-30 |
Regeneron Pharma |
Anti-il-25 antibodies and uses thereof
|
CA2963712A1
(en)
|
2014-10-21 |
2016-04-28 |
Ablynx Nv |
Treatment of il-6r related diseases
|
KR20230158131A
(ko)
|
2014-11-14 |
2023-11-17 |
사노피 바이오테크놀로지 |
Il-4r 길항제의 투여에 의한, 비용종을 동반한 만성 부비동염의 치료 방법
|
MX2017006312A
(es)
|
2014-11-17 |
2017-08-21 |
Regeneron Pharma |
Metodos para el tratamiento tumoral utilizando el anticuerpo biespecifico cd3xcd20.
|
EP3226899A4
(en)
*
|
2014-12-02 |
2018-09-05 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating dry eye disease by administering an il-6r antagonist
|
TWI702229B
(zh)
|
2014-12-19 |
2020-08-21 |
美商再生元醫藥公司 |
流行性感冒病毒血球凝集素之人類抗體
|
TWI710573B
(zh)
|
2015-01-26 |
2020-11-21 |
美商再生元醫藥公司 |
抗伊波拉病毒醣蛋白之人類抗體
|
US10774148B2
(en)
|
2015-02-27 |
2020-09-15 |
Chugai Seiyaku Kabushiki Kaisha |
Composition for treating IL-6-related diseases
|
JP2018508224A
(ja)
|
2015-03-19 |
2018-03-29 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
抗原を結合する軽鎖可変領域を選択する非ヒト動物
|
EA201792298A1
(ru)
|
2015-04-15 |
2018-04-30 |
Регенерон Фармасьютикалз, Инк. |
Способы увеличения силы и функциональности с помощью ингибиторов gdf8
|
JP2016208934A
(ja)
*
|
2015-05-12 |
2016-12-15 |
学校法人日本大学 |
抗イヌインターロイキン−6受容体モノクローナル抗体又は抗体フラグメント及びその利用
|
PL3299810T3
(pl)
|
2015-05-19 |
2021-12-13 |
National Center Of Neurology And Psychiatry |
Sposób określania zastosowania nowej terapii u pacjentów ze stwardnieniem rozsianym (sm)
|
EP3305325A4
(en)
|
2015-06-04 |
2019-01-16 |
National Center of Neurology and Psychiatry |
ACTIVE AGENT FOR THE THERAPY OF MENTAL ILLNESSES WITH IL-6 INHIBITOR AS AN ACTIVE AGENT
|
EA038973B1
(ru)
|
2015-07-06 |
2021-11-17 |
Ридженерон Фармасьютикалз, Инк. |
Полиспецифические антигенсвязывающие молекулы и их применения
|
JOP20160154B1
(ar)
|
2015-07-31 |
2021-08-17 |
Regeneron Pharma |
أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
|
TW202330904A
(zh)
|
2015-08-04 |
2023-08-01 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
CA2995645A1
(en)
|
2015-08-18 |
2017-02-23 |
Regeneron Pharmaceuticals, Inc. |
Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
|
TWI756187B
(zh)
|
2015-10-09 |
2022-03-01 |
美商再生元醫藥公司 |
抗lag3抗體及其用途
|
EP3184547A1
(en)
*
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg antibodies and methods of use
|
US11649262B2
(en)
|
2015-12-28 |
2023-05-16 |
Chugai Seiyaku Kabushiki Kaisha |
Method for promoting efficiency of purification of Fc region-containing polypeptide
|
CN114128676A
(zh)
|
2016-01-13 |
2022-03-04 |
瑞泽恩制药公司 |
具有包括改造的多样性簇的免疫球蛋白重链可变区的非人动物及其用途
|
JP2019509059A
(ja)
|
2016-02-16 |
2019-04-04 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
変異型キヌレニナーゼ遺伝子を有する非ヒト動物
|
JP7166925B2
(ja)
|
2016-03-07 |
2022-11-08 |
サノフィ・バイオテクノロジー |
関節リウマチを処置するための組成物及び方法
|
EP3216461A1
(en)
|
2016-03-07 |
2017-09-13 |
Sanofi Biotechnology |
Compositions and methods for treating rheumatoid arthritis
|
PL3439689T3
(pl)
|
2016-04-08 |
2022-01-31 |
Regeneron Pharmaceuticals, Inc. |
Sposoby leczenia hiperlipidemii inhibitorem angptl8 i inhibitorem angptl3
|
SG11201807885PA
(en)
*
|
2016-04-20 |
2018-10-30 |
Regeneron Pharma |
Compositions and methods for making antibodies based on use of expression-enhancing loci
|
IL262268B1
(en)
|
2016-04-20 |
2024-01-01 |
Regeneron Pharma |
Preparations and methods for the preparation of antibodies based on the use of an amplified expression locus
|
US11352446B2
(en)
|
2016-04-28 |
2022-06-07 |
Regeneron Pharmaceuticals, Inc. |
Methods of making multispecific antigen-binding molecules
|
TWI822521B
(zh)
|
2016-05-13 |
2023-11-11 |
美商再生元醫藥公司 |
藉由投予pd-1抑制劑治療皮膚癌之方法
|
KR20240016444A
(ko)
|
2016-05-20 |
2024-02-06 |
리제너론 파마슈티칼스 인코포레이티드 |
다중 가이드 RNAs를 이용한 면역학적 내성 파괴 방법
|
WO2017201731A1
(en)
*
|
2016-05-27 |
2017-11-30 |
Beijing Vdjbio Co., Ltd. |
Antibodies, composition and kits comprising same, and methods of use thereof
|
WO2017214089A1
(en)
|
2016-06-06 |
2017-12-14 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals expressing antibodies with human lambda light chains
|
AU2017278193B9
(en)
|
2016-06-10 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Anti-GITR antibodies and uses thereof
|
CN116769024A
(zh)
|
2016-06-14 |
2023-09-19 |
瑞泽恩制药公司 |
抗c5抗体及其用途
|
TW201815821A
(zh)
|
2016-07-18 |
2018-05-01 |
美商再生元醫藥公司 |
抗茲卡病毒抗體及使用方法
|
RU2656160C2
(ru)
*
|
2016-08-17 |
2018-05-31 |
Закрытое Акционерное Общество "Биокад" |
Антитело или его антигенсвязывающий фрагмент, способный связываться с рецептором интерлейкина-6 человека
|
WO2018039499A1
(en)
|
2016-08-24 |
2018-03-01 |
Regeneron Pharmaceuticals, Inc. |
Host cell protein modification
|
KR20220151021A
(ko)
|
2016-09-01 |
2022-11-11 |
리제너론 파아마슈티컬스, 인크. |
Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법
|
KR102520731B1
(ko)
|
2016-09-23 |
2023-04-14 |
리제너론 파아마슈티컬스, 인크. |
항-steap2 항체, 항체-약물 컨쥬게이트, 및 steap2 및 cd3에 결합하는 이중특이적 항원-결합 분자, 및 이의 용도
|
PT3515487T
(pt)
|
2016-09-23 |
2023-08-24 |
Regeneron Pharma |
Anticorpos anti-muc16-cd3 biespecíficos e conjugados antimuc16- fármacos
|
RS60886B1
(sr)
|
2016-11-04 |
2020-11-30 |
Regeneron Pharma |
Ne-humane životinje koje imaju konstruisani lokus imunoglobulinskog lamba lakog lanca
|
TWI782930B
(zh)
|
2016-11-16 |
2022-11-11 |
美商再生元醫藥公司 |
抗met抗體,結合met之雙特異性抗原結合分子及其使用方法
|
WO2018094112A1
(en)
|
2016-11-17 |
2018-05-24 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating obesity with anti-angptl8 antibodies
|
CN110072549A
(zh)
|
2016-11-29 |
2019-07-30 |
瑞泽恩制药公司 |
防范阿片样物质成瘾的药物组合物
|
MX2019006131A
(es)
|
2016-11-29 |
2019-08-21 |
Regeneron Pharma |
Metodos para tratar cancer de mama positivo para prlr.
|
AU2017367734A1
(en)
|
2016-12-01 |
2019-06-20 |
Regeneron Pharmaceuticals, Inc. |
Radiolabeled anti-PD-l1 antibodies for immuno-PET imaging
|
TWI784988B
(zh)
|
2016-12-01 |
2022-12-01 |
美商再生元醫藥公司 |
治療發炎症狀的方法
|
EP3558347A1
(en)
|
2016-12-22 |
2019-10-30 |
Regeneron Pharmaceuticals, Inc. |
Method of treating an allergy with allergen-specific monoclonal antibodies
|
TW202311284A
(zh)
|
2017-01-03 |
2023-03-16 |
美商再生元醫藥公司 |
抗金黃色葡萄球菌溶血素a毒素之人類抗體
|
SG11201907208XA
(en)
|
2017-02-10 |
2019-09-27 |
Regeneron Pharma |
Radiolabeled anti-lag3 antibodies for immuno-pet imaging
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
JP7185884B2
(ja)
|
2017-05-02 |
2022-12-08 |
国立研究開発法人国立精神・神経医療研究センター |
Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法
|
KR102329175B1
(ko)
|
2017-06-01 |
2021-11-19 |
리제너론 파마슈티칼스 인코포레이티드 |
Bet v 1에 대한 인간 항체 및 이것의 사용 방법
|
KR20200015932A
(ko)
|
2017-06-07 |
2020-02-13 |
리제너론 파마슈티칼스 인코포레이티드 |
효소 내재화를 위한 조성물 및 방법
|
WO2018234879A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
USE OF IL-1β BINDING ANTIBODIES IN THE TREATMENT OF CANCER
|
WO2018235056A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
IL-1BETA BINDING ANTIBODIES FOR USE IN THE TREATMENT OF CANCER
|
US10806780B2
(en)
|
2017-06-28 |
2020-10-20 |
Regeneron Pharmaceuticals, Inc. |
Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof
|
KR20210084695A
(ko)
|
2017-07-06 |
2021-07-07 |
리제너론 파마슈티칼스 인코포레이티드 |
당단백질을 만들기 위한 세포 배양 과정
|
TWI799432B
(zh)
|
2017-07-27 |
2023-04-21 |
美商再生元醫藥公司 |
抗ctla-4抗體及其用途
|
US20200369774A1
(en)
|
2017-09-13 |
2020-11-26 |
Jiangsu Hengrui Medicine Co., Ltd. |
Il-6r antibody and antigen binding fragment thereof and medical use
|
US10865236B2
(en)
|
2017-09-29 |
2020-12-15 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof
|
KR20200074160A
(ko)
|
2017-10-20 |
2020-06-24 |
가꼬우호우징 효고 이카다이가쿠 |
항il-6 수용체 항체를 함유하는 수술 후의 유착을 억제하기 위한 의약 조성물
|
EP3703818B1
(en)
|
2017-10-30 |
2023-11-01 |
Sanofi Biotechnology |
Il-4r antagonist for use in a method for treating or preventing asthma
|
JP7438937B2
(ja)
|
2017-11-30 |
2024-02-27 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗trkbモノクローナル抗体および使用の方法
|
PL3720279T3
(pl)
|
2017-12-05 |
2023-01-16 |
Regeneron Pharmaceuticals, Inc. |
Myszy posiadające zmodyfikowany sposobami inżynierii łańcuch lekki lambda immunoglobuliny oraz ich zastosowania
|
WO2019118556A1
(en)
|
2017-12-13 |
2019-06-20 |
Regeneron Pharmaceuticals, Inc. |
Anti-c5 antibody combinations and uses thereof
|
SG11202005146VA
(en)
|
2017-12-18 |
2020-06-29 |
Regeneron Pharma |
Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof
|
US11977081B2
(en)
|
2017-12-18 |
2024-05-07 |
Regeneron Pharmaceuticals, Inc. |
ANGPTL8 assay and uses thereof
|
CA3084059A1
(en)
|
2017-12-22 |
2019-06-27 |
Regeneron Pharmaceuticals, Inc. |
System and method for characterizing drug product impurities
|
SG11202006379UA
(en)
|
2018-01-26 |
2020-07-29 |
Regeneron Pharma |
Human antibodies to influenza hemagglutinin
|
EP3746471A1
(en)
|
2018-01-31 |
2020-12-09 |
Regeneron Pharmaceuticals, Inc. |
System and method for characterizing size and charge variant drug product impurities
|
TW202311746A
(zh)
|
2018-02-02 |
2023-03-16 |
美商再生元醫藥公司 |
用於表徵蛋白質二聚合之系統及方法
|
JP2021514609A
(ja)
|
2018-02-28 |
2021-06-17 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ウイルス混入物質を同定するためのシステムおよび方法
|
MA52417A
(fr)
|
2018-03-01 |
2021-01-06 |
Regeneron Pharma |
Procédés de modification de composition corporelle
|
IL307577A
(en)
|
2018-03-19 |
2023-12-01 |
Regeneron Pharma |
In-house capillary electrophoresis tests and reagents
|
EP3774893A1
(en)
|
2018-03-26 |
2021-02-17 |
Regeneron Pharmaceuticals, Inc. |
Anti-pfrh5 antibodies and antigen-binding fragments thereof
|
CN112074538A
(zh)
|
2018-04-30 |
2020-12-11 |
瑞泽恩制药公司 |
结合her2和/或aplp2的抗体和双特异性抗原结合分子、其缀合物和用途
|
AU2019265703A1
(en)
|
2018-05-09 |
2020-11-19 |
Regeneron Pharmaceuticals, Inc. |
Anti-MSR1 antibodies and methods of use thereof
|
TW202016125A
(zh)
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
用於定量及調節蛋白質黏度之系統與方法
|
AU2019269685A1
(en)
|
2018-05-17 |
2020-12-03 |
Regeneron Pharmaceuticals, Inc. |
Anti-CD63 antibodies, conjugates, and uses thereof
|
WO2019241692A1
(en)
|
2018-06-14 |
2019-12-19 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals capable of dh-dh rearrangement in the immunoglobulin heavy chain coding sequences
|
JP2021527424A
(ja)
|
2018-06-19 |
2021-10-14 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
抗因子XII/XIIa抗体およびその使用
|
JP2021527431A
(ja)
|
2018-06-21 |
2021-10-14 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
二重特異性抗psma×抗cd28抗体およびその使用
|
SG11202100221VA
(en)
|
2018-07-19 |
2021-02-25 |
Regeneron Pharma |
Chimeric antigen receptors with bcma specificity and uses thereof
|
EP3823664A1
(en)
|
2018-07-19 |
2021-05-26 |
Regeneron Pharmaceuticals, Inc. |
Bispecific anti-bcma x anti-cd3 antibodies and uses thereof
|
JP7460598B2
(ja)
|
2018-08-10 |
2024-04-02 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
膝および/または股関節痛の安全で効果的な処置用の医薬組成物
|
BR112021003023A2
(pt)
|
2018-08-23 |
2021-05-11 |
Regeneron Pharmaceuticals, Inc. |
anticorpos anti-fc epsilon-r1 alfa (fcer1a), moléculas biespecíficas de ligação ao antígeno que ligam fcer1a e cd3, e usos dos mesmos
|
CA3100035A1
(en)
|
2018-08-27 |
2020-03-05 |
Regeneron Pharmaceuticals, Inc. |
Use of raman spectroscopy in downstream purification
|
WO2020047029A1
(en)
|
2018-08-29 |
2020-03-05 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for treating subjects having rheumatoid arthritis
|
US11754569B2
(en)
|
2018-08-30 |
2023-09-12 |
Regeneron Pharmaceuticals, Inc. |
Methods for characterizing protein complexes
|
WO2020086406A2
(en)
|
2018-10-23 |
2020-04-30 |
Regeneron Pharmaceuticals, Inc. |
Anti-npr1 antibodies and uses thereof
|
CA3117945A1
(en)
|
2018-11-09 |
2020-05-14 |
University Of Massachusetts |
Anti-cfae antibodies and methods of use
|
KR20210093856A
(ko)
|
2018-11-21 |
2021-07-28 |
리제너론 파마슈티칼스 인코포레이티드 |
항-스타필로코쿠스 항체 및 이의 사용
|
EA202191580A1
(ru)
|
2018-12-19 |
2021-11-01 |
Ридженерон Фармасьютикалз, Инк. |
Биспецифичные антитела анти-cd28 x анти-cd22 и их применение
|
SG11202105948TA
(en)
|
2018-12-19 |
2021-07-29 |
Regeneron Pharma |
Bispecific anti-muc16 x anti-cd28 antibodies and uses thereof
|
WO2020128613A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1beta binding antibodies
|
ES2942024T3
(es)
|
2019-01-16 |
2023-05-29 |
Regeneron Pharma |
Métodos para caracterizar enlaces disulfuro
|
MX2021009242A
(es)
|
2019-01-31 |
2021-10-26 |
Sanofi Biotechnology |
Anticuerpo anti-receptor de il-6 para tratar la artritis juvenil idiopatica.
|
WO2020167919A1
(en)
|
2019-02-12 |
2020-08-20 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for using bispecific antibodies to bind complement and a target antigen
|
MX2021010114A
(es)
|
2019-02-21 |
2021-12-10 |
Regeneron Pharma |
Métodos para tratar el cáncer ocular mediante el uso de anticuerpos anti-met y moléculas de unión a antígeno bispecíficas que se unen a met.
|
WO2020178193A1
(en)
|
2019-03-01 |
2020-09-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method of treatment of sarcoidosis
|
MX2021011141A
(es)
|
2019-03-21 |
2022-01-19 |
Regeneron Pharma |
Combinacion de inhibidores de la via de il-4/il-13 y ablacion de celulas plasmaticas para el tratamiento de alergia.
|
MX2021011500A
(es)
|
2019-03-22 |
2021-10-22 |
Regeneron Pharma |
Anticuerpos multiespecificos egfr x cd28.
|
AU2020270966A1
(en)
|
2019-04-10 |
2021-10-28 |
Regeneron Pharmaceuticals, Inc. |
Human antibodies that bind ret and methods of use thereof
|
TW202106712A
(zh)
|
2019-04-24 |
2021-02-16 |
美商再生元醫藥公司 |
類風溼性關節炎之診斷及治療方法
|
TW202106334A
(zh)
|
2019-05-01 |
2021-02-16 |
法商賽諾菲生物技術公司 |
藉由投予il-33拮抗劑治療或預防哮喘之方法
|
US20200363400A1
(en)
|
2019-05-13 |
2020-11-19 |
Regeneron Pharmaceuticals, Inc. |
Competitive Ligand Binding Assays
|
MA56116A
(fr)
|
2019-06-04 |
2022-04-13 |
Stefano Fiore |
Compositions et procédés de traitement de la douleur chez des sujets atteints de polyarthrite rhumatoïde
|
MX2021014893A
(es)
|
2019-06-05 |
2022-03-11 |
Regeneron Pharma |
Animales no humanos que tienen un repertorio de cadena ligera lambda limitado expresado a partir del locus kappa y usos de estos.
|
BR112021023335A2
(pt)
|
2019-06-11 |
2022-01-04 |
Regeneron Pharma |
Anticorpos recombinante isolado ou seu fragmento de ligação ao antígeno e monoclonal isolado ou seu fragmento de ligação ao antígeno, composição farmacêutica, molécula polinucleotídica isolada, vetor, célula, método de diminuição do risco de adquirir infecção por p. aeruginosa, e, métodos de diminuição da carga bacteriana em um sujeito com uma infecção por p. aeruginosa, de aumento da sobrevida ou da probabilidade de sobrevida de um sujeito que sofre de infecção por p. aeruginosa ou de um sujeito que corre risco de infecção por p. aeruginosa, para melhorar ou reduzir a gravidade, a duração ou a frequência de ocorrência de pelo menos um sintoma de uma infecção por p. aeruginosa, para aumentar a sobrevida ou a probabilidade de sobrevida de um sujeito que sofre de fibrose cística
|
US20220249640A1
(en)
*
|
2019-06-14 |
2022-08-11 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against pd-1 and methods of use thereof
|
WO2020252471A1
(en)
*
|
2019-06-14 |
2020-12-17 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against pd-1 and methods of use thereof
|
JP2022537555A
(ja)
|
2019-06-20 |
2022-08-26 |
武田薬品工業株式会社 |
ウイルスベースの遺伝子療法による治療方法
|
US20210032354A1
(en)
|
2019-07-16 |
2021-02-04 |
Sanofi Biotechnology |
Methods for treating or preventing asthma by administering an il-4r antagonist
|
JP2022542559A
(ja)
|
2019-07-24 |
2022-10-05 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Mage-a4特異性を有するキメラ抗原受容体およびそれらの使用
|
WO2021055350A1
(en)
|
2019-09-16 |
2021-03-25 |
Regeneron Pharmaceuticals, Inc. |
Radiolabeled met binding proteins for immuno-pet imaging
|
WO2021061790A1
(en)
|
2019-09-24 |
2021-04-01 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for chromatography use and regeneration
|
EP4051707A1
(en)
|
2019-10-28 |
2022-09-07 |
Regeneron Pharmaceuticals, Inc. |
Anti-hemagglutinin antibodies and methods of use thereof
|
KR20220104797A
(ko)
|
2019-11-25 |
2022-07-26 |
리제너론 파마슈티칼스 인코포레이티드 |
비수성 에멀전을 이용한 지속 방출 제형
|
KR20220110553A
(ko)
|
2019-12-06 |
2022-08-08 |
사노피 바이오테크놀로지 |
Il-33 길항제를 투여하여 copd를 치료하는 방법
|
CA3160352A1
(en)
|
2019-12-06 |
2021-06-10 |
Israel Lowy |
Methods of treating multiple myeloma with bispecific anti-bcma x anti-cd3 antibodies
|
MX2022007958A
(es)
|
2019-12-23 |
2022-10-07 |
Sanofi Biotechnology |
Metodos para tratar o prevenir el asma alergica mediante la administracion de un antagonista de il-33 y/o un antagonista de il-4r.
|
EP4085253B1
(en)
|
2020-01-21 |
2024-03-13 |
Regeneron Pharmaceuticals, Inc. |
Deglycosylation methods for electrophoresis of glycosylated proteins
|
WO2021150970A1
(en)
|
2020-01-22 |
2021-07-29 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Bi-specific chimeric antigen receptor t cells targeting cd83 and interleukin 6 receptor
|
WO2021163076A1
(en)
|
2020-02-10 |
2021-08-19 |
Regeneron Pharmaceuticals, Inc. |
ANTl-TMPRSS2 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS
|
KR20220140802A
(ko)
|
2020-02-11 |
2022-10-18 |
리제너론 파아마슈티컬스, 인크. |
항-acvr1 항체 및 이의 용도
|
MX2022010599A
(es)
|
2020-02-28 |
2022-09-09 |
Regeneron Pharma |
Moleculas biespecificas de union al antigeno que se unen a her2, y metodos de uso de los mismos.
|
BR112022017156A2
(pt)
|
2020-03-06 |
2022-11-08 |
Regeneron Pharma |
Anticorpo isolado ou fragmento de ligação, molécula polinucleotídica isolada, vetor, célula hospedeira isolada, composição farmacêutica, método de tratamento de câncer, e, uso de um anticorpo
|
CR20220552A
(es)
|
2020-04-02 |
2023-01-17 |
Regeneron Pharma |
Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
|
US20230406907A1
(en)
*
|
2020-05-06 |
2023-12-21 |
Sorrento Therapeutics, Inc. |
Neutralizing Antibodies that Bind the SARS-COV-2 S Protein
|
US11884736B2
(en)
|
2020-05-12 |
2024-01-30 |
Regeneron Pharmaceuticals, Inc. |
Antibodies which bind to glucagon-like peptide 1 receptor (GLP1R)
|
JP2023526294A
(ja)
*
|
2020-05-18 |
2023-06-21 |
ビオシオン インコーポレイテッド |
Il6rに結合する抗体及びその使用
|
US20230174657A1
(en)
|
2020-05-26 |
2023-06-08 |
Sanofi Biotechnology |
Compositions comprising an antibody against interleukin-6 receptor for the treatment of rheumatoid arthritis and methods of using same
|
US20240043504A1
(en)
|
2020-05-26 |
2024-02-08 |
Regeneron Pharmaceuticals, Inc. |
Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments
|
BR112022023949A2
(pt)
|
2020-05-29 |
2022-12-27 |
Sanofi Biotechnology |
Composições e métodos para tratar dor não inflamatória em indivíduos com artrite reumatoide
|
US20230227539A1
(en)
*
|
2020-06-16 |
2023-07-20 |
Hifibio (Hk) Limited |
Methods and compositions related to neutralizing antibodies against human coronavirus
|
WO2022032139A1
(en)
*
|
2020-08-07 |
2022-02-10 |
Sorrento Therapeutics, Inc. |
Neutralizing antibodies that bind the sars-cov-2 s protein
|
KR20230051683A
(ko)
|
2020-08-20 |
2023-04-18 |
리제너론 파아마슈티컬스, 인크. |
액티빈 a 길항제를 사용한 심장 기능 장애 및 covid-19의 예방 및 치료 방법
|
US20220064270A1
(en)
|
2020-08-26 |
2022-03-03 |
Regeneron Pharmaceuticals, Inc. |
Method of treating an allergy with allergen-specific monoclonal antibodies
|
CN116209772A
(zh)
|
2020-08-31 |
2023-06-02 |
瑞泽恩制药公司 |
用于提高细胞培养性能和减少天冬酰胺序列变体的天冬酰胺补料策略
|
JP2023540808A
(ja)
|
2020-09-11 |
2023-09-26 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗原特異的抗体の同定及び産生
|
IL301037A
(en)
|
2020-09-18 |
2023-05-01 |
Regeneron Pharma |
Antigen binding molecules that bind CD38 and/or CD28 and uses thereof
|
US20220169739A1
(en)
|
2020-10-05 |
2022-06-02 |
Sanofi Biotechnology |
Methods for treating asthma in pediatric subjects by administering an il-4r antagonist
|
MX2023004434A
(es)
|
2020-10-22 |
2023-05-08 |
Regeneron Pharma |
Anticuerpos anti-fgfr2 y metodos para usarlos.
|
AU2021385363A1
(en)
|
2020-11-25 |
2023-06-08 |
Regeneron Pharmaceuticals, Inc. |
Sustained release formulations using non-aqueous membrane emulsification
|
AU2021401301A1
(en)
|
2020-12-17 |
2023-08-03 |
Regeneron Pharmaceuticals, Inc. |
Fabrication of protein-encapsulating microgels
|
US20220195058A1
(en)
|
2020-12-18 |
2022-06-23 |
Regeneron Pharmaceuticals, Inc. |
Immunoglobulin proteins that bind to npr1 agonists
|
TW202241934A
(zh)
|
2020-12-23 |
2022-11-01 |
美商再生元醫藥公司 |
編碼錨定修飾抗體之核酸及其用途
|
EP4281542A1
(en)
|
2021-01-20 |
2023-11-29 |
Regeneron Pharmaceuticals, Inc. |
Methods of improving protein titer in cell culture
|
WO2022187323A1
(en)
|
2021-03-03 |
2022-09-09 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for quantifying and modifying protein viscosity
|
WO2022187626A1
(en)
|
2021-03-05 |
2022-09-09 |
Regeneron Pharmaceuticals, Inc. |
Anti-sars-cov-2-variant-spike glycoprotein antibodies and antigen-binding fragments
|
BR112023018665A2
(pt)
|
2021-03-26 |
2023-10-03 |
Regeneron Pharma |
Métodos e sistemas para desenvolvimento de protocolos de mistura
|
KR20230171454A
(ko)
|
2021-04-20 |
2023-12-20 |
리제너론 파마슈티칼스 인코포레이티드 |
아르테민에 대한 인간 항체 및 이의 사용 방법
|
CA3219609A1
(en)
|
2021-05-04 |
2022-11-10 |
Regeneron Pharmaceuticals, Inc. |
Multispecific fgf21 receptor agonists and their uses
|
KR20240005854A
(ko)
|
2021-05-04 |
2024-01-12 |
리제너론 파아마슈티컬스, 인크. |
Mage-a4 특이성을 갖는 키메라 항원 수용체 및 이들의 용도
|
CA3218455A1
(en)
|
2021-05-11 |
2022-11-17 |
Harvey CHIN |
Anti-tmprss6 antibodies and uses thereof
|
WO2022253805A1
(en)
*
|
2021-06-01 |
2022-12-08 |
Symphogen A/S |
Anti-nkg2a antibodies and compositions
|
WO2022256383A1
(en)
|
2021-06-01 |
2022-12-08 |
Regeneron Pharmaceuticals, Inc. |
Micropchip capillary electrophoresis assays and reagents
|
TW202317623A
(zh)
|
2021-06-14 |
2023-05-01 |
美商再生元醫藥公司 |
基於il2之治療劑及其使用方法
|
WO2023283134A1
(en)
|
2021-07-05 |
2023-01-12 |
Regeneron Pharmaceuticals, Inc. |
Utilization of antibodies to shape antibody responses to an antigen
|
US20230125469A1
(en)
|
2021-07-14 |
2023-04-27 |
Regeneron Pharmaceuticals, Inc. |
Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments
|
IL310362A
(en)
|
2021-07-26 |
2024-03-01 |
Sanofi Biotechnology |
Methods for the treatment of chronic spontaneous urticaria by administration of an IL-4R antagonist
|
US20230077710A1
(en)
|
2021-09-08 |
2023-03-16 |
Regeneron Pharmaceuticals, Inc. |
HIGH-THROUGHPUT AND MASS-SPECTROMETRY-BASED METHOD FOR QUANTITATING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS
|
TW202328179A
(zh)
|
2021-09-20 |
2023-07-16 |
美商再生元醫藥公司 |
控制抗體異質性之方法
|
TW202331252A
(zh)
|
2021-10-07 |
2023-08-01 |
美商再生元醫藥公司 |
Ph計校準與校正
|
US20230116199A1
(en)
|
2021-10-07 |
2023-04-13 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods of ph modeling and control
|
WO2023069976A1
(en)
|
2021-10-20 |
2023-04-27 |
Sanofi Biotechnology |
Methods for treating prurigo nodularis by administering an il-4r antagonist
|
WO2023070097A2
(en)
|
2021-10-22 |
2023-04-27 |
Regeneron Pharmaceuticals, Inc. |
Factor xi a2 domain-binding antibodies and methods of use thereof
|
WO2023076340A1
(en)
|
2021-10-26 |
2023-05-04 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for generating laboratory water and distributing laboratory water at different temperatures
|
WO2023092052A1
(en)
|
2021-11-19 |
2023-05-25 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for reducing centralized pain
|
US20230250170A1
(en)
|
2021-12-06 |
2023-08-10 |
Regeneron Pharmaceuticals, Inc. |
Antagonist anti-npr1 antibodies and methods of use thereof
|
US20230296559A1
(en)
|
2022-03-18 |
2023-09-21 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for analyzing polypeptide variants
|
WO2023196903A1
(en)
|
2022-04-06 |
2023-10-12 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen-binding molecules that bind and cd3 and tumor associated antigens (taas) and uses thereof
|
US20240002491A1
(en)
|
2022-04-27 |
2024-01-04 |
Regeneron Pharmaceuticals, Inc. |
Methods for selecting patients for treatment with an ngf antagonist
|
US20230416396A1
(en)
|
2022-05-18 |
2023-12-28 |
Regeneron Pharmaceuticals, Inc. |
Multispecific antigen binding molecules that bind cd38 and 4-1bb, and uses thereof
|
WO2024015816A1
(en)
|
2022-07-12 |
2024-01-18 |
Regeneron Pharmaceuticals, Inc. |
Antibodies to ciliary neurotrophic factor receptor (cntfr) and methods of use thereof
|
WO2024047021A1
(en)
|
2022-08-29 |
2024-03-07 |
Sanofi |
Methods for treating chronic inducible cold urticaria by administering an il-4r antagonist
|